Nephrology
Systematic Review: “For the general population of persons with elevated blood pressure, the benefits of trying to achieve a lower blood pressure target rather than a standard target (140/90 mm Hg or less) do not outweigh the harms associated with that intervention.”
12 Jan, 2021 | 01:30h | UTCBlood pressure targets in adults with hypertension – Cochrane Library
Summary: The use of lower blood pressure targets for people with hypertension – Cochrane Library
Related systematic review: Blood pressure targets in people with cardiovascular disease – Cochrane Library
Commentary on Twitter
The use of lower #bloodpressure targets for people with #hypertension https://t.co/W1bF8W7CDD Updated @CochraneHTN systematic review includes 11 randomised controlled trials involving 38,688 adult participants.
— Cochrane (@cochranecollab) December 30, 2020
Study suggests that 7 days of home blood pressure monitoring is likely better than 24h ambulatory monitoring or 3 office measurements
10 Jan, 2021 | 20:17h | UTCEditorial: Which Blood Pressure Measurement Best Predicts Cardiovascular Outcomes?
Commentary: Is Home BP Monitoring the Best Approach For Diagnosing HTN? – American College of Cardiology
Randomized trial: In kidney transplantation, oxygenated cold perfusion preservation is safe and reduces post-transplant complications compared to standard cold perfusion preservation in kidney transplantation
16 Dec, 2020 | 10:06h | UTCOxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Oxygenated hypothermic perfusion reduces post-kidney transplant complications – 2 Minute Medicine
Observational study suggests we should individualize blood pressure targets among critically ill patients with different ranges of pre-illness baseline mean perfusion pressure
16 Dec, 2020 | 10:01h | UTCCommentary: Personalized Pressors – REACT Study Group – Journal Feed
Randomized trial: In acutely ill children, the risk of electrolyte disorders is markedly increased with plasmalike isotonic fluid therapy compared with moderately hypotonic fluid therapy containing 20 mmol/L of potassium
15 Dec, 2020 | 01:25h | UTCRisk of Electrolyte Disorders in Acutely Ill Children Receiving Commercially Available Plasmalike Isotonic Fluids: A Randomized Clinical Trial – JAMA Pediatrics (link to abstract – $ for full-text)
Commentary: Isotonic Fluids Without Potassium Could Be Harmful for Some Acutely Ill Kids – Medscape (free registration required)
Commentary on Twitter
A randomized pragmatic clinical trial shows a high risk of #hypokalemia and a small risk of #hypernatremia in acutely ill children receiving plasma-like fluid therapy https://t.co/FOoJeaSSes @TerhiTapiainen
— JAMA Pediatrics (@JAMAPediatrics) October 27, 2020
Systematic review: Among patients with advanced chronic kidney disease and uremic pruritus, gabapentinoids are the most studied treatments and show the greatest reduction in itch scores
13 Dec, 2020 | 23:16h | UTCInterventions for itch in people with advanced chronic kidney disease – Cochrane Library
Commentary: What is the best treatment for itch in people with chronic kidney disease? – Cochrane Library
Supplement: Lupus in the 21st Century
13 Dec, 2020 | 23:13h | UTCHomepage: Lupus in the 21st Century
Editorial: Lupus in the 21st century
- Classifying and diagnosing systemic lupus erythematosus in the 21st century
- New biomarkers in SLE: from bench to bedside
- Treatment targets in SLE: remission and low disease activity state
- Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
- Lupus nephritis: clinical presentations and outcomes in the 21st century
- The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?
- The patient’s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?
- Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
Spironolactone use is associated with improved outcomes in patients with heart failure with preserved ejection fraction and concomitant resistant hypertension
8 Dec, 2020 | 07:44h | UTC
Practice recommendations for the management of the most common forms of secondary hypertension, including primary aldosteronism, renovascular hypertension, pheochromocytoma, Cushing’s syndrome, and sleep apnea
26 Nov, 2020 | 08:59h | UTC
Cohort study suggests there is no need to choose first-line drug treatment for hypertension according to age and ethnicity – guidelines could be simplified
26 Nov, 2020 | 08:56h | UTCCommentary: Study questions blood pressure drug guidance based on age and ethnicity – British Medical Journal AND Laurie Tomlinson: Shining a light into medicine’s dusty corners – The BMJ Opinion AND UK’s NICE Guidelines for Hypertension Tx Based on Age, Ethnicity May Need Updating – Physician’s Weekly AND
Commentary on Twitter
Current UK guidance on drug treatment for high blood pressure, which differs depending on a patient’s age and ethnicity, could be simplified in line with other international guidelines, suggests new @bmj_latest research @SarahJoSinnott https://t.co/bWLhXoFnV4
— The BMJ (@bmj_latest) November 21, 2020
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:08h | UTCSotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
KDIGO Guideline Synopsis: Diabetes management in chronic kidney disease. Use of ACE inhibitors or ARBs, glycemic monitoring and targets, and choice of antihyperglycemic drugs are covered
11 Nov, 2020 | 09:09h | UTCOriginal guideline: Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more
5 Nov, 2020 | 08:58h | UTCClinical Management of Hyperkalemia – Mayo Clinic Proceedings
The value of urinary sodium assessment in acute heart failure
3 Nov, 2020 | 03:02h | UTC
Case study: Urinary magnesium in the evaluation of hypomagnesemia
2 Nov, 2020 | 02:19h | UTCUrinary Magnesium in the Evaluation of Hypomagnesemia – JAMA (free for a limited period)
KDIGO Controversies Conference on onco-nephrology
30 Oct, 2020 | 01:03h | UTC
Commentary on Twitter
.@goKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer ca. 2020 from @Kidney_Int #Nephpearls#Onconephrology 🦀
👉🏼 https://t.co/u6ANtXdKfy pic.twitter.com/4xJ0gGohoE— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) October 28, 2020
Randomized trial suggests rapid intermittent bolus of hypertonic saline is the best approach for the treatment of symptomatic hyponatremia
27 Oct, 2020 | 09:36h | UTC
For managing symptomatic #hyponatremia, both rapid intermittent bolus (RIB) and slow continuous infusion of hypertonic saline are safe and effective, but RIB achieves a target serum sodium sooner and needs lesser therapeutic re-lowering of serum sodium https://t.co/J4y4BbA855
— JAMA Internal Medicine (@JAMAInternalMed) October 26, 2020
[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes
25 Oct, 2020 | 23:34h | UTCEffect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Finerenone Linked to Reduced Cardiorenal Events for Chronic Kidney Disease – HCPLive
Commentary on Twitter (thread – click for more)
‼️Effect of Finerenone on CKD outcomes in T2DM
⚡️Finerenone decreased risk of CKD progression by 18%
⚡️Finerenone decreased CV morbidity & mortality by 14%
Published in @NEJM today https://t.co/XvshpZZCK4@ASNKidney #Kidneywk pic.twitter.com/FOkxnG1enz
— Aisha Shaikh (@aishaikh) October 23, 2020
Randomized trial: Effects of regional citrate anticoagulation vs. systemic heparin anticoagulation on dialysis filter life span and mortality among critically ill patients with acute kidney injury
25 Oct, 2020 | 23:32h | UTC
Commentary on Twitter
In this RCT, anticoagulation with regional citrate, compared with systemic heparin, resulted in longer filter life span in patients with acute kidney injury receiving continuous kidney replacement therapy https://t.co/fmkawnqjmM #VisualAbstract
— JAMA (@JAMA_current) October 23, 2020
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
20 Oct, 2020 | 01:33h | UTCExecutive summary: 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment – Kidney International
Commentary on Twitter
2020 #KDIGO Diabetes Management in #CKD Guidelinehttps://t.co/G127PgO1fe@deboerih @P_Rossing @goKDIGO pic.twitter.com/3kVNDpAoub
— Kidney International (@Kidney_Int) October 4, 2020
[Abstract Only] Systematic review and meta-analysis of native kidney biopsy complications
20 Oct, 2020 | 01:26h | UTCSystematic Review and Meta-Analysis of Native Kidney Biopsy Complications – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
A meta-analysis found that although native kidney biopsy is an invasive diagnostic procedure, the rates of bleeding complications are low. Complications are more frequently seen after kidney biopsies of hospitalized patients with AKI. https://t.co/kxK6qxX1fc pic.twitter.com/SgCoI505cc
— CJASN (@CJASN) October 15, 2020
[Abstract Only] Meta-analysis: Effect of urate-lowering therapy on cardiovascular and kidney outcomes
20 Oct, 2020 | 01:22h | UTCEffect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
Study found urate-lowering therapy didn't produce benefits on clinical outcomes including major adverse cardiovascular events, all-cause mortality & kidney failure. Insufficient evidence to support urate lowering to improve kidney & cardiovascular outcomes https://t.co/uifm4vikYe pic.twitter.com/3fV60V3Lcx
— CJASN (@CJASN) October 14, 2020
Study: Real-world blood pressure measurements vs. measurements taken in the SPRINT trial
15 Oct, 2020 | 09:00h | UTCCommentaries: A Tale of 2 Blood Pressures – JAMA Internal Medicine AND Real-World BP Measurements vs SPRINT Protocol – Physician’s Weekly
Commentary on Twitter
Incredibly important paper in @JAMAInternalMed demonstrating poor concordance between clinic blood pressure and trial based blood pressure. https://t.co/waLTYk9Lnu
— Stephen Juraschek MD, PhD, FAHA, AHSCP-CHS (@spjuraschek) October 13, 2020
COVID-19 and the kidney
8 Oct, 2020 | 09:02h | UTCCOVID-19 and the kidney – Cleveland Clinic Journal of Medicine
KDOQI clinical practice guideline for nutrition in CKD: 2020 update
6 Oct, 2020 | 00:08h | UTC